Bergen, Norway, 2 March 2021: The Board of Directors in BerGenBio ASA (the
"Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the
share option agreements and in accordance with the authorization granted by the
general meeting on 16 March 2020, resolved to increase the Company's share
capital by NOK 56,159.90 by issuance of 561,599 new shares. The new shares are
subscribed for by an option holder who has requested and is entitled to exercise
options in accordance with the Company's option scheme. The subscription price
is in accordance with the prevailing options price pursuant to the CompanyŽs
option scheme, at an average of NOK 14.82 per share. The options that have been
exercised would have expiry 31[st] March 2021, if not exercised.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,782,158.20 consisting of 87,821,582 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513



Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.